SEARCH:   Advanced

Blood, Vol. 112, Issue 3, 830-835, August 1, 2008 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab Blood Gopal et al. 112: 830 Supplemental materials for: Gopal et al Files in this Data Supplement: Figure S1. Rituximab blocks CD20 binding, but not CD45 (JPG, 134 KB) - (A) Rituximab blocks binding of tositumomab to FL-18 cells (B) but has no impact on CD45 binding by BC8, (C) Rituximab blocks CD20 binding of tositumomab to Granta cells, (D) but has no impact on CD45 binding by BC8. Figure S2. Patient-derived serum blocks CD20 binding (JPG, 32.3 KB) - One-to-one dilutions of serum from 3 rituximab-treated patients blocks CD20 binding by tositumomab to malignant B cells from a rituximab naïve patient. Figure S3. Patient-derived serum does not block CD45 binding (JPG, 29.7 KB) - One-to-one dilutions of serum from 3 rituximab-treated patients has no impact on CD45 binding by BC8 to malignant B cells from a rituximab naïve patient. Figure S4. Rituximab pretreatment impairs anti-CD20 tumor targeting, but not anti-CD45 targeting in Granta and FL-18 xenografts (JPG, 207 KB) - Effect of rituximab pre-treatment on percent injected radioactivity dose per gram (%ID/g) of normal and tumor tissue in Granta xenograft-bearing mice treated with (A) 131I-tositumomab and (B) 125I-BC8. Effect of rituximab pre-treatment on %ID/g of normal and tumor tissue in FL-18 xenograft-bearing mice treated with (C) 131I-tositumomab or (D) 125I-BC8. This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020